PPPCARE II: Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
Study Details
Study Description
Brief Summary
The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: interventional group benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan |
Other: personalized pharmaceutical plan
multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
|
| No Intervention: control group routine management, including medication reconciliation at entry and exit and pharmaceutical analysis of prescriptions |
Outcome Measures
Primary Outcome Measures
- total duration of treatment in days with strong opioids from day of inclusion [6 months]
Secondary Outcome Measures
- number of patients exceeding the optimal duration of treatment with strong opioids defined by the SFETD learned society (French Society for the Study and Treatment of Pain) (3 months) [3 months]
- pain assessment (numerical scale) at first patient call after stopping strong opioids [6 months]
- number of patients exceeding the optimal duration of treatment with strong opioids defined by the CLUD (Pain Control Committee) of Rouen University Hospital (28 days) [28 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient hospitalized in the rheumatology department
-
Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
-
Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion
Exclusion Criteria:
-
Patient with cancer or fibromyalgia already diagnosed at inclusion
-
Patient with poor French language skills
-
Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
-
Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
-
Patient already included in the study
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University Hospital, Rouen
Investigators
- Principal Investigator: Catherine CHENAILLER, Rouen University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020/0426/HP